Shattuck Labs Announces Orphan Drug Designation Granted by the US Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML)

Shattuck Labs, Inc. announced that the US FDA has granted orphan drug designation to lead clinical candidate SL-172154 for the treatment of AML.
[Shattuck Labs]
Press Release